$BHVN News

Biohaven Initiates First-In-Human Dosing For BHV-8100 Pyruvate Kinase M2 Isoform Modulator

Biohaven: Despite Today's Gains, I Remain Skeptical

Biohaven Presents New Patient Data From Its BHV-1300 MoDE Degrader For Graves' Disease, BHV-1400 Trap Degrader For IgA Nephropathy

HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target

Biohaven Presents New Data From Kv7.2/7.3 Channel Activator Program To Treat Focal Epilepsy

Morgan Stanley Maintains Overweight on Biohaven, Lowers Price Target to $18

RBC Capital Maintains Outperform on Biohaven, Lowers Price Target to $22

Biohaven Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

Citigroup Maintains Buy on Biohaven, Raises Price Target to $17

Biohaven Completes Enrollment In Phase 2 Proof-Of-Concept Study Of Taldefgrobep Alfa For Obesity; Topline Data Expected In 2H 2026

TD Cowen Maintains Buy on Biohaven, Raises Price Target to $30

HC Wainwright & Co. Maintains Neutral on Biohaven, Lowers Price Target to $10

RBC Capital Maintains Outperform on Biohaven, Raises Price Target to $23

Biohaven Ltd. (NYSE:BHVN) Posts Narrower-Than-Expected Q4 2025 Loss Amid Clinical Progress

Biohaven Q4 Adj. EPS $(1.21) Misses $(1.06) Estimate

BHVN stock has given up its prior gain. Biohaven shares were trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $9 to $22.

RBC Capital Upgrades Biohaven (BHVN)

Biohaven shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $9 to $22.

RBC Capital Upgrades Biohaven to Outperform, Raises Price Target to $22

Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know